<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860183</url>
  </required_header>
  <id_info>
    <org_study_id>CHMerkur</org_study_id>
    <nct_id>NCT01860183</nct_id>
  </id_info>
  <brief_title>Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis</brief_title>
  <official_title>Comparison of 3g Versus 2g Mycophenolate Mofetil in Combination With Tacrolimus on Progression of Chronic Histology Changes in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Hospital Merkur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Hospital Centre Osijek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Rijeka</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Hospital Merkur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of chronic changes (scarring) in transplanted kidney tissue is a major cause of
      long-term kidney function deterioration and ultimately graft loss. It results from both
      immunologic and non-immunologic mechanisms. Mycophenolate mofetil (MMF) is immunosuppressive
      drug used for prevention of rejection after kidney transplant, usually in combination with a
      calcineurin inhibitor (tacrolimus or cyclosporine), with or without corticosteroids. Besides
      immunosuppression, MMF may also have direct antifibrotic properties. Tacrolimus has potent
      immunosuppressive effects and is the cornerstone of contemporary posttransplant
      immunosuppressive therapy in kidney recipients. However, it is also nephrotoxic. The
      hypothesis of the present study is that in the setting of similar net immunosuppression,
      higher dose of MMF (3 g daily) will result in slower progression of kidney fibrosis during
      first year posttransplant as compared to MMF 2 g daily. To test this hypothesis, the present
      study will randomly assign low immunological risk kidney transplant recipients to either 2g
      or 3 g MMF daily, in combination with tacrolimus, with, or without maintenance steroids. All
      patients will have kidney biopsy at implantation and at 12 months after transplantation. Main
      outcome will be 1-year change in chronic kidney histology (interstitial fibrosis) assessed by
      protocol biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of interstitial fibrosis (ci)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first acute rejection episode</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of other chronic scores</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft loss</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of infections requiring hospitalization</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of CMV viremia</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of BK viremia</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of BK nephropathy</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Development of donor-specific antibodies</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Renal morphology and hemodynamics assessed by ultrasound</measure>
    <time_frame>1 year</time_frame>
    <description>Subset of study patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>MMF 3g daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MMF 2 g daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.</description>
    <arm_group_label>MMF 3g daily</arm_group_label>
    <arm_group_label>MMF 2 g daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. first kidney or kidney-pancreas transplantation

          2. CDC PRA &lt;=20%

        Exclusion Criteria:

          1. dual kidney transplantation

          2. AB0 incompatible transplantation

          3. 0 biopsy ci, ct, cv, or ah score &gt;=2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Mladen Knotek, MD</last_name>
    <phone>+38512431393</phone>
    <email>mladen.knotek1@zg.t-com.hr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bojana Maksimović, MD</last_name>
    <phone>+38512431393</phone>
    <email>b.maximovic@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Hospital Merkur</name>
      <address>
        <city>Zagreb</city>
        <state>HR</state>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mladen Knotek, MD</last_name>
      <phone>385994888231</phone>
      <email>mladen.knotek1@zg.t-com.hr</email>
    </contact>
    <contact_backup>
      <last_name>Bojana Maksimović, MD</last_name>
      <phone>+38512431393</phone>
      <email>b.maximovic@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>chronic allograft dysfunction</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

